HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Ocular onchocerciasis — Clinical Guidelines

Overview

Onchocerciasis, also known as river blindness, is a parasitic disease caused by Onchocerca volvulus, leading to significant ocular and skin damage, particularly blindness, in endemic tropical regions 1 5.

Diagnosis

Clinical Examination: Signs include skin nodules, itching, and ocular symptoms such as interstitial keratitis, band keratopathy, and chorioretinal scarring 5.

Microfilariae Detection: Skin snip microscopy to detect microfilariae in the gluteal region 4.

Ocular Involvement: Fundus examination for Hissette-Ridley lesions and slit-lamp examination for anterior segment changes 5.

Management

First-Line Treatment: Community-directed treatment with ivermectin (CDTI) at 150 μg/kg single dose 4 6.

Adverse Reactions Monitoring: Regular follow-up to monitor for frequent but generally mild adverse reactions, with severe reactions being rare 6.

Special Populations

Pediatrics: Emerging focus on vaccine candidates like Ov-RAL-2 and Ov-103 for infants and children below 5 years to prevent early-onset disease 1.

Adverse Reactions: Frequent adverse reactions noted in pediatric populations treated with ivermectin, though generally well-tolerated 6.

Key Recommendations

Implement community-directed treatment with ivermectin (CDTI) to reduce microfilaridermia and clinical manifestations, aiming for elimination 4 (Evidence: Strong).

Monitor for adverse reactions following ivermectin treatment, particularly in pediatric populations, despite generally favorable acceptance 6 (Evidence: Moderate).

Strengthen efforts towards onchocerciasis elimination to also address associated conditions like onchocerciasis-associated epilepsy (OAE) 3 (Evidence: Expert opinion).

References

1 Nebangwa DN, Shey RA, Shadrack DM, Shintouo CM, Yaah NE, Yengo BN et al.. Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials. PloS one 2024. link 2 Gaiya DD, Muhammad A, Aimola IA, Udu SK, Balarabe SA, Auta R et al.. Potential of . Journal of biomolecular structure & dynamics 2023. link 3 Colebunders R, Mandro M, Njamnshi AK, Boussinesq M, Hotterbeekx A, Kamgno J et al.. Report of the first international workshop on onchocerciasis-associated epilepsy. Infectious diseases of poverty 2018. link 4 Samuel A, Belay T, Yehalaw D, Taha M, Zemene E, Zeynudin A. Impact of Six Years Community Directed Treatment with Ivermectin in the Control of Onchocerciasis, Western Ethiopia. PloS one 2016. link 5 Kluxen G, Hoerauf A. The significance of some observations on African ocular onchocerciasis described by Jean Hissette (1888-1965). Bulletin de la Societe belge d'ophtalmologie 2008. link 6 Kipp W, Bamhuhiiga J, Rubaale T, Büttner DW. Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis. The American journal of tropical medicine and hygiene 2003. link

Ocular onchocerciasis